These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18320288)

  • 21. The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer.
    Martínez-Bosch N; Guerrero PE; Moreno M; José A; Iglesias M; Munné-Collado J; Anta H; Gibert J; Orozco CA; Vinaixa J; Fillat C; Viñals F; Navarro P
    Oncotarget; 2016 Jul; 7(30):48265-48279. PubMed ID: 27374084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expansion of endothelial surface by an increase of vessel diameter during tumor angiogenesis in experimental and hepatocellular and pancreatic cancer.
    Ryschich E; Schmidt E; Maksan SM; Klar E; Schmidt J
    World J Gastroenterol; 2004 Nov; 10(21):3171-4. PubMed ID: 15457566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suramin inhibits the growth of malignant mesothelioma in vitro, and in vivo, in murine flank and intraperitoneal models.
    Cook JW; Sterman DH; Singhal S; Smythe WR; Kaiser LR
    Lung Cancer; 2003 Dec; 42(3):263-74. PubMed ID: 14644513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies on mechanisms of interferon-gamma action in pancreatic cancer using a data-driven and model-based approach.
    Lange F; Rateitschak K; Fitzner B; Pöhland R; Wolkenhauer O; Jaster R
    Mol Cancer; 2011 Feb; 10(1):13. PubMed ID: 21310022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model.
    Zhang X; Galardi E; Duquette M; Delic M; Lawler J; Parangi S
    Clin Cancer Res; 2005 Mar; 11(6):2337-44. PubMed ID: 15788685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular structure and microcirculation of experimental pancreatic carcinoma in rats.
    Schmidt J; Ryschich E; Daniel V; Herzog L; Werner J; Herfarth C; Longnecker DS; Gebhard MM; Klar E
    Eur J Surg; 2000 Apr; 166(4):328-35. PubMed ID: 10817332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The growth pattern and microvasculature of pancreatic tumours induced with cultured carcinoma cells.
    Mäkinen K; Loimas S; Nuutinen P; Eskelinen M; Alhava E
    Br J Cancer; 2000 Feb; 82(4):900-4. PubMed ID: 10732764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Magnetic resonance imaging in an orthotopic rat model: blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth.
    Bangard C; Gossmann A; Papyan A; Tawadros S; Hellmich M; Bruns CJ
    Int J Cancer; 2005 Mar; 114(1):131-8. PubMed ID: 15523683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of suramin on anastomotic colon tumors in a rat model.
    Lauwers P; Hubens G; Hendriks J; Vermeulen P; Schuerwegh A; Stevens WJ; De Clerck LS; Dirix L; Van Marck E; Hubens A; Eyskens E
    Eur Surg Res; 1999; 31(4):347-56. PubMed ID: 10449994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiogenesis inhibition with TNP-470, 2-methoxyestradiol, and paclitaxel in experimental pancreatic carcinoma.
    Ryschich E; Werner J; Gebhard MM; Klar E; Schmidt J
    Pancreas; 2003 Mar; 26(2):166-72. PubMed ID: 12604915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of suramin on human esophageal cancer cells in vitro and in vivo.
    Shin R; Naomoto Y; Kamikawa Y; Tanaka N; Orita K
    Scand J Gastroenterol; 1997 Aug; 32(8):824-8. PubMed ID: 9282976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.
    Zhang Y; Song S; Yang F; Au JL; Wientjes MG
    J Pharmacol Exp Ther; 2001 Nov; 299(2):426-33. PubMed ID: 11602651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mast cells and angiogenesis in pancreatic ductal adenocarcinoma.
    Longo V; Tamma R; Brunetti O; Pisconti S; Argentiero A; Silvestris N; Ribatti D
    Clin Exp Med; 2018 Aug; 18(3):319-323. PubMed ID: 29492715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer.
    Guha S; Eibl G; Kisfalvi K; Fan RS; Burdick M; Reber H; Hines OJ; Strieter R; Rozengurt E
    Cancer Res; 2005 Apr; 65(7):2738-45. PubMed ID: 15805273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
    Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
    Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
    Conrad C; Ischenko I; Köhl G; Wiegand U; Guba M; Yezhelyev M; Ryan AJ; Barge A; Geissler EK; Wedge SR; Jauch KW; Bruns CJ
    Anticancer Drugs; 2007 Jun; 18(5):569-79. PubMed ID: 17414626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.
    Olive KP; Jacobetz MA; Davidson CJ; Gopinathan A; McIntyre D; Honess D; Madhu B; Goldgraben MA; Caldwell ME; Allard D; Frese KK; Denicola G; Feig C; Combs C; Winter SP; Ireland-Zecchini H; Reichelt S; Howat WJ; Chang A; Dhara M; Wang L; Rückert F; Grützmann R; Pilarsky C; Izeradjene K; Hingorani SR; Huang P; Davies SE; Plunkett W; Egorin M; Hruban RH; Whitebread N; McGovern K; Adams J; Iacobuzio-Donahue C; Griffiths J; Tuveson DA
    Science; 2009 Jun; 324(5933):1457-61. PubMed ID: 19460966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting angiogenesis in pancreatic cancer: rationale and pitfalls.
    Whipple C; Korc M
    Langenbecks Arch Surg; 2008 Nov; 393(6):901-10. PubMed ID: 18210149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
    Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
    J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.